Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell

Shinobu Sagawa1, Yoshitaka Tomoda2, Jun Shikama1

  • 1Respiratory Medicine, Itabashi Chuo Medical Center, Tokyo, JPN.

Cureus
|January 1, 2026
PubMed
Summary

This case report details tumor lysis syndrome (TLS) in a patient with non-small-cell lung cancer (NSCLC) treated with selpercatinib. It highlights the importance of early recognition and management of TLS, even without traditional risk factors.